Dear Colleague:

We are asking for your help in protecting young children and people 65 and older against influenza this season by implementing prompt antiviral treatment when flu is suspected. We are urging you to “think flu.” Currently, influenza activity in the U.S. is high overall and is likely to continue for weeks. H3N2 viruses have been most common so far. There are typically more hospitalizations and deaths in children younger than 2 years and people 65 years and older during seasons when H3N2 viruses predominate. It is important that we do everything we can to protect people in these two age groups from flu. The first and most important step for flu prevention is getting a flu vaccine; however, preliminary vaccine effectiveness results of about 23% indicate that the vaccine is working less well this season, likely because of substantial antigenic and genetic drift among circulating H3N2 viruses, which are dominating so far this season. So, we are urging you to also “think flu treatment.” In the context of widespread circulation of H3N2 and reduced vaccine effectiveness, prompt antiviral treatment of severely ill and high risk patients becomes even more important as a second line of defense in reducing flu complications and death.

Your recommendations make a difference to your patients. Here are some key points to consider about the importance of flu vaccination and prompt treatment for flu, particularly in high risk patients:

- **Children younger than 2 years, and people 65 and older are at high risk for complications from the flu. These two age groups have the highest flu hospitalization rates.**
- **Antiviral drugs are an important second line of defense to treat flu illness. (They are not a substitute for vaccination.)**
  - Data indicate that flu antiviral drugs can reduce symptoms and prevent serious flu complications.
  - For high risk patients, antiviral drugs can mean the difference between a milder illness and a hospital stay.
  - Antiviral drugs are under-utilized. A recent study showed that only 19% of high risk outpatients who had the flu were treated with flu antiviral drugs.
  - CDC recommends that all severely ill people and people who are at high risk of serious flu complications with suspected flu be treated with flu antiviral drugs as soon as possible (without confirmatory testing).
  - Studies show that flu antiviral drugs work best for treatment when they are started within 2 days of getting sick. However, starting them later may still be helpful.
  - There are three FDA-approved influenza antiviral drugs recommended by CDC this season. The brand names for these are Tamiflu® (generic name oseltamivir), Relenza® (generic name zanamivir), and Rapivab® (generic name peramivir). Peramivir was approved in December 2014. It is given by IV.
- **Even though vaccine effectiveness for H3N2 is reduced this season, CDC continues to recommend vaccination because it may still provide some protection, including reducing more severe flu outcomes like hospitalization and death. Also, flu vaccines protect against three or four different viruses and it’s possible that other viruses will circulate later in the season.**
Your role in ensuring your patients are protected against influenza is crucial. We hope this information will be beneficial to you as you treat your patients this flu season. More information can be found at: http://www.cdc.gov/flu/antivirals/index.htm.

Anne Schuchat, MD  
RADM, United States Public Health Service  
Assistant Surgeon General  
Director, National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention

Errol R. Alden, MD, FAAP  
Executive Director/CEO  
American Academy of Pediatrics

Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA  
Executive Vice President and CEO  
American Pharmacists Association

Jonathan Sobel PA-C, MBA  
Chair, Health of the Public Commission  
American Academy of Physician Assistants

James L. Madara, MD  
Executive Vice President, CEO  
American Medical Association

Patrick Joseph, MD  
President  
National Foundation for Infectious Diseases

Reid B. Blackwelder, MD  
Chair, Board of Directors  
American Academy of Family Physicians

David W. Kimberlin, MD, FPIDS  
President  
Pediatric Infectious Disease Society

Elena Rios, MD, MSPH  
President & CEO  
National Hispanic Medical Association

Lawrence L. Sanders, Jr, MD, MBA  
President  
National Medical Association

Additional organizations:  
American College of Physicians  
Infectious Disease Society of America